[{"id":"306f2837-4ae2-43cc-8471-5706f09281e5","acronym":"ELAINE 3","url":"https://clinicaltrials.gov/study/NCT05696626","created_at":"2023-01-25T16:59:42.976Z","updated_at":"2025-02-25T12:38:31.246Z","phase":"Phase 3","brief_title":"Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation","source_id_and_acronym":"NCT05696626 - ELAINE 3","lead_sponsor":"Sermonix Pharmaceuticals Inc.","biomarkers":" ER","pipe":" | ","alterations":" ESR1 mutation","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • Fablyn (lasofoxifene)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-24"},{"id":"251108c9-4fb9-4d2a-b2b3-ca1b2c0bb048","acronym":"","url":"https://clinicaltrials.gov/study/NCT01273168","created_at":"2021-01-18T05:09:01.740Z","updated_at":"2025-02-25T13:39:00.081Z","phase":"Phase 1","brief_title":"Endoxifen in Adults With Hormone Receptor Positive Solid Tumors","source_id_and_acronym":"NCT01273168","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-21"},{"id":"907c18db-1f38-4071-a1e3-b3af86377f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05941520","created_at":"2023-07-12T16:10:13.477Z","updated_at":"2025-02-25T13:49:53.635Z","phase":"Phase 2","brief_title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","source_id_and_acronym":"NCT05941520","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • acolbifene"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/23/2024","start_date":" 08/23/2024","primary_txt":" Primary completion: 08/23/2027","primary_completion_date":" 08/23/2027","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-02-21"},{"id":"e2cd3260-cd72-4639-a5ac-6d252bb0c83c","acronym":"ELAINEII","url":"https://clinicaltrials.gov/study/NCT04432454","created_at":"2021-01-18T21:20:42.852Z","updated_at":"2025-02-25T14:51:49.300Z","phase":"Phase 2","brief_title":"Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","source_id_and_acronym":"NCT04432454 - ELAINEII","lead_sponsor":"Sermonix Pharmaceuticals Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Fablyn (lasofoxifene)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 09/29/2020","start_date":" 09/29/2020","primary_txt":" Primary completion: 01/28/2025","primary_completion_date":" 01/28/2025","study_txt":" Completion: 01/28/2025","study_completion_date":" 01/28/2025","last_update_posted":"2025-02-13"},{"id":"55cb45be-28da-426b-95b0-c684a21c9966","acronym":"","url":"https://clinicaltrials.gov/study/NCT02311933","created_at":"2021-01-18T10:56:52.952Z","updated_at":"2025-02-25T16:58:44.113Z","phase":"Phase 2","brief_title":"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT02311933","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • NCOA3","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive","tags":["ER • NCOA3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zonalta (Z-endoxifen hydrochloride) • Soltamox (tamoxifen citrate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 05/28/2015","start_date":" 05/28/2015","primary_txt":" Primary completion: 11/06/2020","primary_completion_date":" 11/06/2020","study_txt":" Completion: 02/04/2025","study_completion_date":" 02/04/2025","last_update_posted":"2025-02-03"},{"id":"41c64d00-75dd-4fa2-9ce1-9e342496ddc1","acronym":"ELAINE 1","url":"https://clinicaltrials.gov/study/NCT03781063","created_at":"2021-01-18T18:42:03.161Z","updated_at":"2024-07-02T16:35:08.944Z","phase":"Phase 2","brief_title":"Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","source_id_and_acronym":"NCT03781063 - ELAINE 1","lead_sponsor":"Sermonix Pharmaceuticals Inc.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER L536Q • ER Y537C","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER L536Q • ER Y537C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Fablyn (lasofoxifene)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/20/2019","start_date":" 09/20/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-18"},{"id":"2638658d-5de1-4c1e-afa0-e9fef20584a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01327781","created_at":"2021-01-18T05:24:42.319Z","updated_at":"2024-07-02T16:35:17.724Z","phase":"Phase 1","brief_title":"Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT01327781","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • ER • PGR • AKT1 • mTOR • IGF1R • NCOA3 • PI3K","pipe":" | ","alterations":" ER positive • HER-2 expression • EGFR expression","tags":["EGFR • HER-2 • ER • PGR • AKT1 • mTOR • IGF1R • NCOA3 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 expression • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 03/25/2011","start_date":" 03/25/2011","primary_txt":" Primary completion: 03/05/2017","primary_completion_date":" 03/05/2017","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2024-02-26"},{"id":"24050ecc-e087-49d7-8b3c-491960aa21ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT00200174","created_at":"2021-01-18T00:40:51.455Z","updated_at":"2024-07-02T16:35:43.977Z","phase":"","brief_title":"Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease","source_id_and_acronym":"NCT00200174","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PGR","pipe":"","alterations":" ","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • raloxifene hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 07/01/1999","start_date":" 07/01/1999","primary_txt":" Primary completion: 07/01/2003","primary_completion_date":" 07/01/2003","study_txt":" Completion: 08/01/2008","study_completion_date":" 08/01/2008","last_update_posted":"2023-07-04"},{"id":"6d778386-93bc-43df-aca0-788f12fcfb93","acronym":"PROMISE","url":"https://clinicaltrials.gov/study/NCT02694809","created_at":"2021-01-18T13:09:19.110Z","updated_at":"2024-07-02T16:35:56.250Z","phase":"Phase 2","brief_title":"The PROMISE Study: Duavee in Women With DCIS","source_id_and_acronym":"NCT02694809 - PROMISE","lead_sponsor":"Northwestern University","biomarkers":" HER-2 • PGR • CD36 • PTGS2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2 • PGR • CD36 • PTGS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 01/01/2017","start_date":" 01/01/2017","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-02-07"},{"id":"5a276f52-0dd5-4e55-baf2-a9b438493c7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02448771","created_at":"2021-01-18T11:44:00.142Z","updated_at":"2024-07-02T16:36:01.989Z","phase":"Phase 1/2","brief_title":"A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer","source_id_and_acronym":"NCT02448771","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 07/09/2015","start_date":" 07/09/2015","primary_txt":" Primary completion: 08/12/2019","primary_completion_date":" 08/12/2019","study_txt":" Completion: 03/03/2021","study_completion_date":" 03/03/2021","last_update_posted":"2022-10-24"},{"id":"3bb45c0b-82f2-4050-8899-8d4a9efd15c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02993159","created_at":"2021-01-18T14:43:26.101Z","updated_at":"2024-07-02T16:36:37.043Z","phase":"Phase 2b","brief_title":"Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast","source_id_and_acronym":"NCT02993159","lead_sponsor":"Northwestern University","biomarkers":" ER • IGF1 • CD68","pipe":" | ","alterations":" ER positive","tags":["ER • IGF1 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e afimoxifene • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/31/2017","start_date":" 05/31/2017","primary_txt":" Primary completion: 07/15/2022","primary_completion_date":" 07/15/2022","study_txt":" Completion: 07/15/2023","study_completion_date":" 07/15/2023","last_update_posted":"2020-12-21"},{"id":"b9f63f6c-7641-41f9-8fa1-59c2bb338d66","acronym":"","url":"https://clinicaltrials.gov/study/NCT00853996","created_at":"2021-01-18T03:15:11.465Z","updated_at":"2024-07-02T16:37:14.836Z","phase":"Phase 2","brief_title":"Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer","source_id_and_acronym":"NCT00853996","lead_sponsor":"University of Kansas Medical Center","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e acolbifene"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 12/01/2010","primary_completion_date":" 12/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2018-01-17"},{"id":"61af50c9-eb81-4f95-aa89-37849ac3c9be","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005879","created_at":"2021-01-17T23:51:42.337Z","updated_at":"2024-07-02T16:37:21.599Z","phase":"Phase 2","brief_title":"LY353381 in Preventing Breast Cancer in Women With Hyperplasia","source_id_and_acronym":"NCT00005879","lead_sponsor":"University of Kansas Medical Center","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e arzoxifene (LY353381)"],"overall_status":"Completed","enrollment":" Enrollment 199","initiation":"Initiation: 08/01/2000","start_date":" 08/01/2000","primary_txt":" Primary completion: 07/01/2008","primary_completion_date":" 07/01/2008","study_txt":" Completion: 07/01/2008","study_completion_date":" 07/01/2008","last_update_posted":"2017-05-30"},{"id":"52033cea-4db4-4ed4-a10c-0a59a9dbab52","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005886","created_at":"2021-01-17T23:51:44.325Z","updated_at":"2024-07-02T16:37:26.542Z","phase":"Phase 1","brief_title":"Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer","source_id_and_acronym":"NCT00005886","lead_sponsor":"University of Kansas Medical Center","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Soltamox (tamoxifen citrate) • arzoxifene (LY353381)"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 07/01/2000","start_date":" 07/01/2000","primary_txt":" Primary completion: 08/01/2002","primary_completion_date":" 08/01/2002","study_txt":" Completion: 08/01/2002","study_completion_date":" 08/01/2002","last_update_posted":"2017-01-13"}]